U.S. Healthcare Services Stock News

NasdaqCM:EOSE
NasdaqCM:EOSEElectrical

Is Eos Energy Enterprises (EOSE) Fully Priced As Defense And Revenue News Builds?

Eos Energy Enterprises (EOSE) is in focus after securing a Golden Dome for America contract to deploy its Z3 zinc-based long-duration storage for national defense, along with record preliminary quarterly revenue guidance and expanding utility-scale project activity. See our latest analysis for Eos Energy Enterprises. Despite the defense contract and growing utility-scale project activity, the stock’s recent momentum has been weak. The 30-day share price return is down 46.01% and the...
NYSE:GS
NYSE:GSCapital Markets

Is Goldman Sachs’ Earnings Beat, Higher Dividend And New Debt Issuance Altering The Investment Case For GS?

In mid-July 2026, Goldman Sachs reported second-quarter net income of US$6,628 million and sharply higher earnings per share versus a year earlier, while also lifting its quarterly dividend to US$5.00 per share and executing US$4,000 million of share repurchases under an ongoing buyback program. Alongside these results, Goldman Sachs completed and announced multiple fixed and variable-rate bond offerings totaling several billions of dollars, underlining its continued use of the debt markets...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)

Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis patients, with complete renal response at 6 months as the primary endpoint. This post-approval trial builds on LUPKYNIS’s status as the only FDA-approved oral therapy for lupus nephritis and the only treatment to show a statistically significant increase in complete renal response at 6 months,...
NYSE:JAN
NYSE:JANHealth Care REITs

3 Interest Rate Sensitive Stocks Investors Are Watching As Fed Rate Signals Turn Murky

Interest rate sensitive stocks are back in focus as investors try to read a quiet new Fed chair and cooling inflation data that hint at steady borrowing costs. When policy signals are fuzzy and volatility risks rise, companies with stronger balance sheets and lower risk profiles can stand out within sectors tied closely to interest rates. Using our Interest Rate Sensitive Sectors screener, this article will walk through 3 stocks that appear well positioned for the current debate over the...
NYSE:ECL
NYSE:ECLChemicals

Ecolab (ECL) In Focus As Oppenheimer Upgrade Tests An Undervalued Narrative

Oppenheimer upgrade puts Ecolab in focus Oppenheimer’s upgrade of Ecolab (ECL) to Outperform, citing improving momentum in its core businesses along with growing contributions from its Global High-Tech segment, has pushed the stock back onto investors’ radar. See our latest analysis for Ecolab. At a share price of $272.83, Ecolab’s stock has been relatively steady in the short term, with a modest 30 day share price return of 1.38%, while its 3 year total shareholder return of 48.80% points to...
NasdaqGS:BWIN
NasdaqGS:BWINInsurance

How Shifting Sentiment Around Growth and Risk Will Impact Baldwin Insurance Group (BWIN) Investors

In recent weeks, Baldwin Insurance Group has attracted renewed investor attention as market participants reassess the insurer’s growth profile, recent performance metrics, and overall risk-reward balance in light of shifting sentiment rather than specific corporate announcements. This sentiment-driven reappraisal is occurring despite a weaker longer-term shareholder outcome, highlighting how quickly expectations around Baldwin’s earnings outlook and risk exposure can change. With this...
NYSE:GXO
NYSE:GXOLogistics

GXO Logistics (GXO) Renews Castorama Partnership, Is The Recent Upside Already Priced In?

GXO Logistics (GXO) stock is back in focus after the company renewed its long running partnership with Castorama for Moissy-Cramayel operations in France, reinforcing its role in the retailer’s nationwide supply chain. See our latest analysis for GXO Logistics. Against this backdrop, GXO Logistics’ recent 7 day share price return of 6.8% and 1 month share price return of 11.12% stand in contrast to a 3 month share price decline of 8.79% and a 3 year total shareholder return that is down...
NYSE:HGV
NYSE:HGVHospitality

Hilton Grand Vacations (HGV) Following Its Loan Refinance Is The Stock Fully Valued

Hilton Grand Vacations (HGV) recently refinanced its existing Term Loan B, replacing the US$849 million facility due 2028 with an amended US$850 million term loan maturing in 2033, while keeping pricing at SOFR plus 200. See our latest analysis for Hilton Grand Vacations. Hilton Grand Vacations’ refinancing news comes after a mixed stretch for the stock, with the share price down 5.29% over 30 days but still achieving a 9.78% year to date share price return and a 24.79% five year total...
NYSE:BKSY
NYSE:BKSYProfessional Services

BlackSky Technology (BKSY) Could Be 45% Undervalued Following Gen 3 Defense Contract Wins

BlackSky Technology (BKSY) is back in focus after securing several U.S. government research and development contracts for its Gen-3 AI constellation, which is centered on real-time space-based intelligence and battle damage assessment capabilities. See our latest analysis for BlackSky Technology. Despite the contract wins, BlackSky Technology’s 30 day share price return is down 23.46% and the 90 day share price return is down 40.70%. However, the 3 year total shareholder return is up 44.47%,...
NasdaqCM:RIOT
NasdaqCM:RIOTSoftware

Riot Platforms (RIOT) Pulls Back Sharply, Is The Stock Now Cheap?

Riot Platforms Stock Reaction To Recent Attention Riot Platforms (RIOT) has come into focus after its stock became one of the most searched, as investors weigh largely unchanged earnings estimates alongside expectations for a current quarter loss and potential earnings growth next fiscal year. See our latest analysis for Riot Platforms. The recent spike in attention on Riot Platforms comes after a sharp pullback, with the stock down 35.02% on a 1 month share price return basis, yet still...
NasdaqGS:BTSG
NasdaqGS:BTSGHealthcare

Is BrightSpring Health Services (BTSG) Undervalued On Its Move Into The S&P 400?

Index reshuffle puts BrightSpring Health Services in focus BrightSpring Health Services (BTSG) moved from the S&P 600 to the S&P 400 Health Care index, a reshuffle that can change how index funds and institutional investors trade the stock. See our latest analysis for BrightSpring Health Services. BrightSpring Health Services has seen strong momentum build, with an 84.09% year to date share price return and a very large 254.42% 1 year total shareholder return. The latest index shift and...
NasdaqGS:UFCS
NasdaqGS:UFCSInsurance

United Fire Group (UFCS) Stock Looks Near Fair Value On Earnings

United Fire Group stock has delivered a strong 141.1% return over the past 5 years, and after such a run the shares at around US$51 no longer look obviously cheap, especially with the broad valuation checks leaning toward a richer pricing. Over 5 years, United Fire Group has returned 141.1%. This puts extra weight on whether current investors are paying up for that past performance. Future growth in premiums and underwriting quality can support the current share price. Any pressure on claims...
NYSE:BE
NYSE:BEElectrical

Bloom Energy (BE) Following The $1.7b AI Funding Deal And Its Valuation Case

Bloom Energy (BE) has jumped into the spotlight after Industrial Development Funding and Oaktree agreed to provide a $1.7b financing package to deploy its fuel cell systems for Nebius’ AI cloud infrastructure projects. See our latest analysis for Bloom Energy. The Nebius deal comes after a volatile stretch for Bloom Energy’s stock, with the 30 day share price return down about 35% and the 7 day return also lower. At the same time, the year to date share price return is 118% and the 1 year...
NYSE:OHI
NYSE:OHIHealth Care REITs

High Dividend Yield Stocks for Steady Income as Rate Hike Fears Ease

With semiconductor stocks under pressure, oil prices and bond yields on the move, and inflation data easing the immediate threat of rate hikes, income investors are rethinking where to look for reliable cash flows. High dividend yield stocks can offer a steadier stream of returns when market sentiment swings from optimism to caution. This article uses a High Dividend Yield Stocks screener, filtered for companies with market caps over $100m and expected dividend yields of at least 3%, to...
NasdaqGS:CATY
NasdaqGS:CATYBanks

Is Cathay General Bancorp (CATY) Still Reasonable After Its Q1 Pop?

Cathay General Bancorp stock has nearly doubled investors' money over the past five years, yet its Excess Returns intrinsic value estimate suggests the shares may still be pricing in a discount to what the business could be worth. At the same time, the broader valuation checks paint a more balanced picture rather than a straightforward bargain. Cathay General Bancorp has returned 98.3% over 5 years, which puts the current share price in the context of a strong longer term run for...
NasdaqGS:SBUX
NasdaqGS:SBUXHospitality

Starbucks (SBUX) Stock May Be 49% Overvalued Following AI Cost Cutting Plans

Starbucks stock has gained 25.6% year to date, yet the current price sits at a premium to what both its Discounted Cash Flow (DCF) intrinsic value estimate and market based valuation checks suggest. This raises questions about how much optimism is already reflected in the share price. The 25.6% year to date return shows investors have rewarded Starbucks quickly, which puts more pressure on future execution to justify the current valuation. Plans to cut costs through in house AI software and...
NasdaqCM:GDYN
NasdaqCM:GDYNIT

3 Supply Chain Software Stocks For Retailers Facing The EU Clothing Waste Ban

The EU’s move to ban the destruction of unsold clothes and footwear is forcing fashion groups to rethink how they plan, move, and clear inventory. Instead of quietly scrapping excess stock, brands may need better tools for forecasting demand, managing returns, and finding new resale or outlet channels. That shift puts the spotlight on supply chain and inventory technology providers that help retailers keep stock levels under tighter control. This article looks at 3 stocks that are directly...
NasdaqGS:MKTX
NasdaqGS:MKTXCapital Markets

MarketAxess (MKTX) Stock May Be Reasonable After A 75% Five Year Fall

MarketAxess Holdings has seen its share price fall sharply over the past five years, yet the current intrinsic value estimate from the Excess Returns model suggests the stock may trade at a sizable discount to its underlying worth. That gap, alongside a mixed overall value score, puts the focus squarely on whether the recent share price weakness has gone too far or is closer to fair. The stock is down 74.5% over the past five years, which puts long term holders deeply underwater and raises...
NYSE:ICE
NYSE:ICECapital Markets

Intercontinental Exchange (ICE) After Record Gas Trading And The Case For Undervalued Shares

Intercontinental Exchange (ICE) recently reported record open interest in its North American Financial Natural Gas futures and options, a milestone tied to shifting LNG exports, new infrastructure, and weather driven demand swings. See our latest analysis for Intercontinental Exchange. Despite record volumes in natural gas contracts and a Q1 update that exceeded analyst revenue and EPS expectations, Intercontinental Exchange's share price has slipped, with a 90 day share price return down...
NasdaqGS:FSBC
NasdaqGS:FSBCBanks

The Bull Case For Five Star Bancorp (FSBC) Could Change Following Dividend Hike And Lodi Branch Expansion

Five Star Bancorp recently declared a past second-quarter 2026 cash dividend of US$0.25 per share, payable on August 10, 2026, to shareholders of record as of August 3, 2026, and continued its regional build-out with a new branch in Lodi, California. The combination of a regular cash payout and physical network expansion highlights management’s ongoing emphasis on shareholder returns alongside measured growth in its Northern California footprint. We’ll now examine how the Lodi branch opening...
NYSE:STT
NYSE:STTCapital Markets

State Street (STT) Posted Record Assets, Is The Upside Already Priced In?

State Street (STT) is back in focus after its second quarter results showed net income of $1,084 million and higher earnings per share, alongside record assets under custody, administration and management. See our latest analysis for State Street. State Street's share price has moved sharply higher this year, with a year to date share price return of 41.40% and a 30 day share price return of 8.43%. The 1 year total shareholder return of 72.52% and 3 year total shareholder return of 185.60%...
NasdaqGS:IBKR
NasdaqGS:IBKRCapital Markets

Interactive Brokers (IBKR) Stock Looks Pricey For New Investors Today

After Interactive Brokers Group stock delivered a very large 5 year total return of about 5.1x, the current checks point to a more cautious picture, with the Excess Returns intrinsic value estimate sitting close to the market price while earnings based multiples lean expensive. Over the past 5 years, Interactive Brokers Group has returned roughly 511.7%, which puts added pressure on today’s buyers to justify the valuation with future cash flows. Recent expansion of its electronic brokerage...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story?

Alnylam Pharmaceuticals recently presented at the Alzheimer’s Association International Conference 2026 in London, sharing Phase 1 and Phase 2 updates on its RNAi candidate mivelsiran for early-onset and Down syndrome-associated Alzheimer’s disease, as well as progress on ALN-5288 and other neuroscience programs with Regeneron. The company reported long-term biomarker reductions and a favorable safety profile for mivelsiran, while fully enrolling its Phase 2 cerebral amyloid angiopathy...
NasdaqGS:ERAS
NasdaqGS:ERASBiotechs

The Bull Case For Erasca (ERAS) Could Change Following ERAS-0015 IP Dispute And Fundraising Moves

Earlier this month, Erasca announced updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors, alongside a completed follow-on equity offering of US$550.00 million and a broad shelf registration filing. Shortly afterward, a securities class action lawsuit was filed following allegations that ERAS-0015 infringes Revolution Medicines’ intellectual property and misappropriates trade secrets, adding legal and scientific uncertainty...